Provided by Tiger Trade Technology Pte. Ltd.

INVESCO PHARMACEUTICALS ETF

124.09
-0.6464-0.52%
Post-market: 124.090.00000.00%19:30 EDT
Volume:26.40K
Turnover:3.29M
Market Cap:542.27M
PE:6.43
High:125.99
Open:125.88
Low:124.09
Close:124.74
52wk High:131.68
52wk Low:90.01
Shares:4.37M
Float Shares:4.37M
Volume Ratio:0.78
T/O Rate:0.60%
Dividend:1.06
Dividend Rate:0.85%
EPS(TTM):19.29
EPS(LYR):21.73
ROE:23.89%
ROA:0.60%
PB:1.63
PE(LYR):5.71

Loading ...

Abbott Laboratories Stock Underperforms Thursday When Compared to Competitors

Dow Jones
·
Yesterday

AbbVie Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Yesterday

Champions Oncology Q1 Revenue Rises on Research Services Business

Reuters
·
Yesterday

Insight Guru Flags Valuation Flip as Merck Trades at 52.2x Operating Profit vs Lilly 25.3x

Reuters
·
Yesterday

AbbVie Declares Quarterly Cash Dividend of $1.73 a Share

Reuters
·
Yesterday

Abbvie - Declares Qtrly Cash Dividend of $1.73 Per Share

THOMSON REUTERS
·
Yesterday

Amgen’s New Repatha Plaque Trial: What Investors Should Watch

TIPRANKS
·
Yesterday

AbbVie’s Eye Implant Study Delivers Fresh Real‑World Clarity for Investors

TIPRANKS
·
Yesterday

Dow's 300-Point Drop Led by Losses in Shares of Nvidia Corp., Amgen

Dow Jones
·
Sep 10

Wachtell Dealmaker Jumps to Linklaters to Bolster US Buildout

Reuters
·
Sep 10

Johnson & Johnson Announces R$ 0.3 Per Unit Dividend for 3Q 2026

Reuters
·
Sep 10

Eli Lilly is Maintained at Reduce by HSBC

Dow Jones
·
Sep 10

Eli Lilly’s GLP-1 Windfall to Fund Push into Women’s Health - Bloomberg News

Reuters
·
Sep 10

AbbVie Says Atogepant Met Primary, Secondary Endpoints in Phase 3 Menstrual Migraine Study

MT Newswires Live
·
Sep 10

AbbVie’s atogepant shows positive Phase 3 results in menstrual migraine

TIPRANKS
·
Sep 10

Abbvie - Atogepant Safety Results Consistent with Known Profile; no New Safety Signals

THOMSON REUTERS
·
Sep 10

Abbvie - Atogepant Meets Primary and All Eight Ranked Secondary Endpoints in Phase 3 Luna Study

THOMSON REUTERS
·
Sep 10

Abbvie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine

THOMSON REUTERS
·
Sep 10

Abbvie - Atogepant Shows Significant Improvements Across Multiple Endpoints Versus Placebo

THOMSON REUTERS
·
Sep 10

Johnson & Johnson receives CE Marking for ACUVUE OASYS MAX

TIPRANKS
·
Sep 10